Globally, prostate cancer is the most common malignancy among men and there is no biomarker for defining tumour invasion and progression. Guanosine-5′triphosphate (GTP)-binding RAS-like 3 (ARHI) is a tumour suppressor gene that has been found to be downregulated in the prostate cancer cell line PC-3. MicroRNA 221 and 222 have been shown to regulate ARHI expression negatively. This study evaluated tissue samples from patients with prostate cancer (n = 35) that were designated as aggressive or non-aggressive according to their Gleason grade.
Introduction
Prostate cancer is the most common malignancy among men and, globally, is the second most common overall cause of cancer-related death. 1 In the USA, an estimated 3% of men die of prostatic adenocarcinoma. 2 Although prostate cancer is less frequently encountered in China than in the USA, its known incidence, including tumours that are at an early stage of disease, has increased dramatically due to prostate specific antigen (PSA) testing. 3 PSA has long been recognized as the most important tumour marker for prostate cancer. 3 Prostate cancer is unique among malignant tumours because its natural history is relatively slow. Prevention is, however, not possible.
Guanosine-5′-triphosphate (GTP)-binding RAS-like 3 (ARHI) is a novel imprinted tumour suppressor gene located on D Lin, F Cui, Q Bu et al. ARHI and microRNA 221 and 222 in prostate cancer chromosome 1p31, the expression of which is lost in ovarian and breast cancers and decreased in prostate cancer cell lines. 4, 5 This gene encodes a novel small GTP-binding protein that belongs to the Ras/Rap superfamily. Despite its homology with the oncogene RAS, ARHI exhibits the characteristics of a tumour suppressor gene. Although little is known about its function, multiple mechanisms (including genomic imprinting, loss of heterozygosity, aberrant methylation and transcriptional regulation) appear to participate in silencing of the ARHI gene in cancer. 4 MicroRNAs are short RNA molecules with an average of 22 nucleotides. They are posttranscriptional regulators that bind to complementary sequences on target mRNA transcripts resulting in translational repression and gene silencing. 6, 7 Several microRNAs have been reported to be associated with cancer. 8, 9 Furthermore, the microRNAs 221 and 222 have been shown to mediate ARHI gene expression in the prostate cancer cell line PC-3. 5 Downregulation of ARHI by microRNAs 221 and 222 may be due to direct binding to the ARHI 3′ untranslated region. 5 The present study investigated the clinical significance of the expression of the ARHI gene and microRNAs 221 and 222 in prostate cancer by evaluating the relationship between disease aggressiveness and ARHI and microRNAs 221 and 222 expression in patients with prostate cancer.
Patients and methods

STUDY POPULATION
Consecutive patients with a diagnosis of prostate cancer (based on pathology) who attended the Urology Department, The First Affiliated Hospital of Suzhou University, Suzhou, China in February and March 2009 were recruited into this retrospective study. None of the patients had received chemotherapy or radiotherapy prior to the start of the study. There were no other specific inclusion or exclusion criteria.
Prostate cancer tissues were collected by laser capture microdissection to avoid contamination with healthy tissue. Samples were divided into two groups according to their Gleason grade: 3 tumours of Gleason grade < 7 were designated as non-aggressive and those of Gleason grade ≥ 7 were designated as aggressive.
The study protocol was approved by the Ethical Review Committee of The First Affiliated Hospital of Suzhou University. All patients provided written informed consent to participate in this study.
ANALYSES OF ARHI AND MICRORNA 221 AND 222 EXPRESSION
Total RNA was extracted from prostate cancer tissue samples using RNeasy™ columns (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Total RNA (1 µg) was reverse transcribed into cDNA using the NCode™ miRNA First-Strand cDNA Synthesis Kit (Clontech Laboratories, Mountain View, CA, USA).
Relative expression of the ARHI gene and of microRNAs 221 and 222 was assessed by real-time reverse transcription-polymerase chain reaction (RT-PCR) using 1 µg of cDNA and SYBR ® Green Real-time Master Mix and RT-PCR reagents (Applied Biosystems, Foster City, CA, USA) and a C1000 Touch TM Thermal Cycler (Bio-Rad, Hercules, CA, USA) according to the manufacturers' instructions. Expression of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control.
The primer sequences used were: ARHI forward primer TCTCTCCGAGCAGCGCA, reverse primer TGGCAGCAGGAGACCC; microRNA 221 and 222 forward primer TGTGAGACCATTTGGGTGAA, reverse primer D Lin, F Cui, Q Bu et al. ARHI and microRNA 221 and 222 in prostate cancer TGTGTTCGTTAGGCAACAGC; and GAPDH forward primer GTGGACCTGACCTGCC GTCT, reverse primer GGAGGAGTGGGTGTC GCTGT. The thermal cycling programme involved preliminary denaturation at 95°C for 10 min, followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 56°C for 30 s and elongation at 72°C for 30 s, followed by a final elongation step at 72°C for 10 min.
Using GAPDH as the internal control, the levels of ARHI mRNA and microRNA 221 and 222 were analysed by relative quantification according to the real-time RT-PCR kit instructions.
STATISTICAL ANALYSES
Data are presented as mean ± SD. Student's t-test was used for comparison of aggressive versus non-aggressive tumours. A P-value < 0.05 was considered to be statistically significant.
Results
Of the 35 patients recruited to the study with a clinical diagnosis of prostate cancer, 18 had non-aggressive (Gleason grade < 7) prostate cancer (mean age 65 years, range 43 -86 years) and 17 had aggressive (Gleason grade ≥ 7) prostate cancer (mean age 69 years, range 36 -81 years).
A significantly lower level of ARHI mRNA was found in aggressive compared with nonaggressive prostate cancer samples (P = 0.001, Fig. 1 ). In tissue samples from aggressive prostate cancers, the mean ± SD level of ARHI mRNA was 9.6 ± 1.2 relative to GAPDH compared with 28.3 ± 2.3 for nonaggressive cancers.
A significantly higher level of microRNAs 221 and 222 was found in aggressive compared with non-aggressive prostate cancer samples (P = 0.001, Fig. 2 ). In tissue samples from aggressive prostate cancers, the mean ± SD level of microRNA 221 and 
Discussion
Despite the high sensitivity of PSA analysis, 3 prostate cancer continues to be a common malignancy and cause of death. 1 Identification of molecular markers of early and late events in prostate cancer progression is critical for prognostic strategies.
Epigenetic alteration in gene promoters is believed to be an early event in neoplastic progression. 10, 11 In prostate cancer, some genes that are involved in the repair of damaged DNA, tumour suppression, cell cycle control and cell adhesion molecules are regulated by methylation of their promoter regions. 12 -15 The glutathione S-transferases (GSTs) are, for example, involved in protecting cells from DNA damage, and methylation of the GST isoform π promoter has been detected in prostate cancer tissues. 16, 17 Similarly, CD44 is an integral membrane glycoprotein that plays a role in cell adhesion 18 and acts as a suppressor of metastasis in prostate cancer. Hyper methylation of CpG islands in the promoter region of CD44 leads to a decrease in CD44 expression. 19 Suppression of CD44 is associated with tumour progression and metastasis. These various processes are associated with tumourigenesis of prostate cancer.
The novel small GTP-binding protein, ARHI, exhibits the characteristics of a tumour suppressor; its expression is decreased in ovarian and breast cancer and its re-expression suppresses the growth of ovarian and breast cancer cells. 4 The ARHI gene consists of two exons: the first contains only the 5′-non-coding region, whereas the second contains the entire protein-coding region. The PCR primers used in the present study were designed to amplify both exons. As expected, significantly lower expression of MicroRNAs are small, non-coding, singlestranded RNAs that regulate gene expression by affecting the stability or translational efficiency of target mRNAs. Altered expression of microRNAs is associated with the development, invasion, metastases and prognosis of prostate cancer. Regulation of the growth, differentiation and apoptosis of carcinoma cells by microRNAs has been investigated. 20 -22 MicroRNAs have been found to be abnormally expressed in prostate cancer. 23 -25 Furthermore, the expression of microRNA 221 and 222 has been found to be upregulated in prostate cancer tissue compared with normal prostate tissue. 26, 27 Expression of microRNA 221 and 222 was significantly higher in aggressive versus non-aggressive prostate cancer tissue in the present study. MicroRNA 221 and 222 binds to p27 kip1 , leading to tumour growth, 28 and this may be one of the mechanisms underlying their role in prostate cancer.
In a prostate cancer cell line, 5 the cancer suppressor gene ARHI was found to be downregulated by direct binding with microRNA 221 and 222. Similarly, expression of the ARHI gene was significantly downregulated in aggressive compared with non-aggressive prostate cancer tissue samples in the present study, which may be explained by the upregulation of microRNA 221 and 222. The data are limited, however, by the small sample size and more studies on larger patient samples are needed to confirm the relationship between ARHI and microRNA 221 and 222 expression.
In summary, the present study showed that ARHI expression was significantly lower in aggressive versus non-aggressive prostate cancer tissue samples, whereas the level of expression of microRNA 221 and 222 was significantly higher in aggressive cancers compared with non-aggressive cancers. This suggests a possible inverse relationship between the expression of these two genes. Whether ARHI and microRNA 221 and 222 could be considered as biomarkers for the aggressiveness of prostate cancer requires further investigation.
